kabutan
N225

68,713.80

+0.59%

TOPIX

4,197.20

+0.51%

USDJPY

159.29

-0.15%

CHUGAI PHARMACEUTICAL CO., LTD.(4519) Summary

4519
TSE Prime
CHUGAI PHARMACEUTICAL CO., LTD.
Result
6,933
JPY
-242
(-3.37%)
Aug 14, 3:30 pm JST
43.52
USD
Aug 14, 2:30 am EDT
PER
PBR
5.63
Yield
1.90%
Margin Trading Ratio
54.23
PTS
outside of trading hours
6,930
Aug 14, 6:37 pm JST
Stock Price
Aug 14, 2026
Opening Aug 14, 9:00 am
7,121 JPY 44.66 USD
Previous Close Aug 13
7,175 JPY 45.01 USD
High Aug 14, 9:00 am
7,121 JPY 44.66 USD
Low Aug 14, 10:33 am
6,852 JPY 42.98 USD
Volume
4,618,700
Trading Value
0.03T JPY 0.20B USD
VWAP
6953.3 JPY 43.66 USD
Minimum Trading Value
693,300 JPY 4,352 USD
Market Capitalization
11.64T JPY 0.07T USD
Number of Trades
10,149
Liquidity & Number of Trades
As of Aug 14, 2026
Liquidity
High
1-Year Average
7,560
1-Year High Apr 27, 2026
27,979
Margin Trading
Date Short Interest Long Margin Positions Ratio
Aug 7, 2026 26,000 1,410,000 54.23
Jul 31, 2026 28,900 1,367,200 47.31
Jul 24, 2026 40,300 1,158,900 28.76
Jul 17, 2026 22,400 1,197,700 53.47
Jul 10, 2026 33,100 1,159,600 35.03
Company Profile
CHUGAI PHARMACEUTICAL CO., LTD. is a major pharmaceutical company. As a subsidiary of Roche, it has expanded its product line, including Tamiflu. The company's main focus is on anticancer drugs and rheumatoid arthritis treatments.
Sector
Pharmaceuticals
CHUGAI PHARMACEUTICAL CO., LTD. is a pharmaceutical company specializing in the research, development, manufacturing, and sales of pharmaceuticals, operating under the Swiss pharmaceutical giant Roche. In Japan, the company sells its own products through authorized dealers, while overseas it has sales bases in Europe, Taiwan, China, and other regions. Manufacturing is carried out at the company's domestic and international factories, as well as through contracted partners. As a member of the Roche Group, Chugai purchases some raw materials from Roche and distributes some products internationally through Roche's network. The company focuses on developing innovative drugs, particularly in the fields of cancer treatment and rheumatoid arthritis, while pursuing global business expansion.